Antibiotic Treatment for Haemophilus influenzae and Streptococcus Group B Infections

Haemophilus influenzae Treatment

The American Academy of Pediatrics recommends amoxicillin-clavulanate as first-line therapy for Haemophilus influenzae infections in outpatient settings, due to increasing β-lactamase production, with a dosage of 625 mg three times daily orally for 7 days in adults 1, 2
The European Respiratory Society suggests that for children under 12 years, co-amoxiclav (amoxicillin component 90 mg/kg/day in 2 divided doses) is an appropriate treatment option 2, 3
For alternative regimens in cases of penicillin allergy, macrolides (such as clarithromycin 500 mg twice daily or azithromycin) or respiratory fluoroquinolones may be considered 1, 2
The Infectious Diseases Society of America recommends that in areas with documented low β-lactamase prevalence, ampicillin alone remains an acceptable treatment option 5, 6

The American College of Obstetricians and Gynecologists recommends ampicillin as the drug of choice for invasive Group B Streptococcus infections, with alternative therapy options including ceftriaxone or cefotaxime for penicillin-allergic patients 6
The Centers for Disease Control and Prevention suggest that penicillin G (benzyl penicillin) 1-4 million units IV every 2-4 hours is an alternative therapy option for Group B Streptococcus infections 6

The Infectious Diseases Society of America recommends a minimum of 48-72 hours of therapy beyond clinical improvement or bacterial eradication, with shorter courses (5-7 days) acceptable for uncomplicated pneumonia with adequate clinical response 7

The World Health Organization warns that H. influenzae is developing increasing β-lactamase production (up to 25% in some regions) and widespread trimethoprim-sulfamethoxazole resistance, making it essential to monitor resistance patterns 4
The American Academy of Otolaryngology-Head and Neck Surgery recommends avoiding macrolides as monotherapy for H. influenzae due to poor coverage, and notes that cephalexin, cefaclor, and loracarbef have inadequate activity against H. influenzae (only 20% susceptibility) 9